Login to Your Account



Elan Sells European Prialt Rights To Eisai For $100M

By Karen Pihl-Carey


Friday, February 10, 2006
Elan Corp. plc decided to sell the European rights to its pain product Prialt, but is keeping U.S. rights, where the drug already is being sold. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription